Spine-Tech's premarket approval (PMA) for BAK/L accepted for filing:
This article was originally published in Clinica
Spine-Tech (US) has received notification from the US FDA that the company's PMA application for the BAK/L interbody fusion system has been accepted for filing. The PMA has also been granted expedited review because the lower re-operation rate reported indicates a potential benefit to public health, Spine-Tech says.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.